Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 8, 2013, Pages 2037-2051

  Geekiyanage, Hirosha ^a   Upadhye, Aditi ^a   Chan, Christina ^a,b,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Michigan State University   (United States)

^c Michigan State University   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Inhibition; MicroRNA; Serine palmitoyltransferase; Tau hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CERAMIDE; CYCLOSERINE; MICRORNA; MICRORNA 137; MICRORNA 181C; MICRORNA 29A; MICRORNA 29B; MICRORNA 9; SERINE PALMITOYLTRANSFERASE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; CERAMIDES; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; MOLECULAR TARGETED THERAPY; PEPTIDE FRAGMENTS; PHOSPHORYLATION; SERINE C-PALMITOYLTRANSFERASE; TAU PROTEINS;

EID: 84877633354     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.02.001     Document Type: Article

References (94)

1. Adams J.M., Pratipanawatr T., Berria R., Wang E., DeFronzo R.A., Sullards M.C., Mandarino L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53:25-31.
2. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
3. Bailey S.A., Zidell R.H., Perry R.W. Relationships between organ weight and body/brain weight in the rat: what is the best analytical endpoint?. Toxicol. Pathol. 2004, 32:448-466.
4. Becker I., Wang-Eckhardt L., Yaghootfam A., Gieselmann V., Eckhardt M. Differential expression of (dihydro)ceramide synthases in mouse brain: oligodendrocyte-specific expression of CerS2/Lass2. Histochem. Cell Biol. 2008, 129:233-241.
5. Becker K., Freude S., Zemva J., Stohr O., Krone W., Schubert M. Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo. Neurosci. Lett. 2012, 516:306-310.
6. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
7. Chabrier M.A., Blurton-Jones M., Agazaryan A.A., Nerhus J.L., Martinez-Coria H., LaFerla F.M. Soluble abeta promotes wild-type tau pathology in vivo. J. Neurosci. 2012, 32:17345-17350.
8. Chessell I.P., Procter A.W., Francis P.T., Bowen D.M. D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Res. 1991, 565:345-348.
9. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
10. Choi M.D. The regulation of ceramide content and insulin resistance in skeletal muscle 2006, Ball State University, In.
11. Chu F.S., Li G.Y. Simultaneous occurrence of fumonisin B1 and other mycotoxins in moldy corn collected from the People's Republic of China in regions with high incidences of esophageal cancer. Appl. Environ. Microbiol. 1994, 60:847-852.
12. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A 2003, 100:11735-11740.
13. Costantini C., Ko M.H., Jonas M.C., Puglielli L. A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. Biochem. J. 2007, 407:383-395.
14. Cutler R.G., Pedersen W.A., Camandola S., Rothstein J.D., Mattson M.P. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 2002, 52:448-457.
15. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2004, 101:2070-2075.
16. Ebina M., Futai E., Tanabe C., Sasagawa N., Kiso Y., Ishiura S. Inhibition by KMI-574 leads to dislocalization of BACE1 from lipid rafts. J. Neurosci. Res. 2009, 87:360-368.
17. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160:113-123.
18. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A 2001, 98:5856-5861.
19. Fenn T.D., Stamper G.F., Morollo A.A., Ringe D. A side reaction of alanine racemase: transamination of cycloserine. Biochemistry 2003, 42:5775-5783.
20. Gable K., Slife H., Bacikova D., Monaghan E., Dunn T.M. Tsc3p is an 80-amino acid protein associated with serine palmitoyltransferase and required for optimal enzyme activity. J. Biol. Chem. 2000, 275:7597-7603.
21. Geekiyanage H., Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid {beta}, novel targets in sporadic Alzheimer's disease. J. Neurosci. 2011, 31:14820-14830.
22. Geekiyanage H., Jicha G.A., Nelson P.T., Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp. Neurol. 2012, 235:491-496.
23. Gomez-Ramos A., Diaz-Nido J., Smith M.A., Perry G., Avila J. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J. Neurosci. Res. 2003, 71:863-870.
24. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007, 64:354-362.
25. Gulbins E., Kolesnick R. Raft ceramide in molecular medicine. Oncogene 2003, 22:7070-7077.
26. Han X., M Holtzman D., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
27. Hanada K., Hara T., Nishijima M. Purification of the serine palmitoyltransferase complex responsible for sphingoid base synthesis by using affinity peptide chromatography techniques. J. Biol. Chem. 2000, 275:8409-8415.
28. Hanada K., Hara T., Nishijima M., Kuge O., Dickson R.C., Nagiec M.M. A mammalian homolog of the yeast LCB1 encodes a component of serine palmitoyltransferase, the enzyme catalyzing the first step in sphingolipid synthesis. J. Biol. Chem. 1997, 272:32108-32114.
29. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell. Biol. 2008, 9:139-150.
30. Haughey N.J., Bandaru V.V., Bae M., Mattson M.P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 2010, 1801:878-886.
31. He X., Huang Y., Li B., Gong C.X., Schuchman E.H. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 2010, 31:398-408.
32. Hebert S.S., Horre K., Nicolai L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N., Kauppinen S., Delacourte A., De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. U. S. A 2008, 105:6415-6420.
33. Henry M.S., Passmore A.P., Todd S., McGuinness B., Craig D., Johnston J.A. The development of effective biomarkers for Alzheimer's disease: a review. Int. J. Geriatr. Psychiatry 2012, 28:331-340.
34. Hojjati M.R., Li Z., Zhou H., Tang S., Huan C., Ooi E., Lu S., Jiang X.C. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 2005, 280:10284-10289.
35. Holland W.L., Brozinick J.T., Wang L.P., Hawkins E.D., Sargent K.M., Liu Y., Narra K., Hoehn K.L., Knotts T.A., Siesky A., Nelson D.H., Karathanasis S.K., Fontenot G.K., Birnbaum M.J., Summers S.A. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell. Metab. 2007, 5:167-179.
36. Hur J.Y., Welander H., Behbahani H., Aoki M., Franberg J., Winblad B., Frykman S., Tjernberg L.O. Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J. 2008, 275:1174-1187.
37. Ichi I., Nakahara K., Kiso K., Kojo S. Effect of dietary cholesterol and high fat on ceramide concentration in rat tissues. Nutrition 2007, 23:570-574.
38. Imbimbo B.P., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M., Windisch M. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 2009, 156:982-993.
39. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U. S. A 2011, 108:5819-5824.
40. Julien C., Tremblay C., Phivilay A., Berthiaume L., Emond V., Julien P., Calon F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol. Aging 2010, 31:1516-1531.
41. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J. Biol. Chem. 2005, 280:36815-36823.
42. Kimura T., Ono T., Takamatsu J., Yamamoto H., Ikegami K., Kondo A., Hasegawa M., Ihara Y., Miyamoto E., Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 1996, 7:177-181.
43. Klatt E.C. The Internet pathology laboratory for medical eductaion 2012, University of Utah eccles health sciences library, Savannah, . Accessed April, 2012. http://library.med.utah.edu/WebPath/webpath.html#MENU.
44. Kluepfel D., Bagli J., Baker H., Charest M.P., Kudelski A. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J. Antibiot. (Tokyo) 1972, 25:109-115.
45. Lanzillotta A., Sarnico I., Benarese M., Branca C., Baiguera C., Hutter-Paier B., Windisch M., Spano P., Imbimbo B.P., Pizzi M. The gamma-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci 2011, 45:22-31.
46. Lee S.J., Liyanage U., Bickel P.E., Xia W., Lansbury P.T., Kosik K.S. A detergent-insoluble membrane compartment contains A beta in vivo. Nature Med. 1998, 4:730-734.
47. Lowther J., Yard B.A., Johnson K.A., Carter L.G., Bhat V.T., Raman M.C., Clarke D.J., Ramakers B., McMahon S.A., Naismith J.H., Campopiano D.J. Inhibition of the PLP-dependent enzyme serine palmitoyltransferase by cycloserine: evidence for a novel decarboxylative mechanism of inactivation. Mol. Biosyst. 2010, 6:1682-1693.
48. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
49. Malashkevich V.N., Strop P., Keller J.W., Jansonius J.N., Toney M.D. Crystal structures of dialkylglycine decarboxylase inhibitor complexes. J. Mol. Biol. 1999, 294:193-200.
50. Mattson M.P., Cutler R.G., Jo D.G. Alzheimer peptides perturb lipid-regulating enzymes. Nat. Cell Biol. 2005, 7:1045-1047.
51. Merrill A.H., Nixon D.W., Williams R.D. Activities of serine palmitoyltransferase (3-ketosphinganine synthase) in microsomes from different rat tissues. J. Lipid Res. 1985, 26:617-622.
52. Myhrer T., Paulsen R.E. Infusion of D-cycloserine into temporal-hippocampal areas and restoration of mnemonic function in rats with disrupted glutamatergic temporal systems. Eur. J. Pharmacol. 1997, 328:1-7.
53. Noland B.W., Newman J.M., Hendle J., Badger J., Christopher J.A., Tresser J., Buchanan M.D., Wright T.A., Rutter M.E., Sanderson W.E., Muller-Dieckmann H.J., Gajiwala K.S., Buchanan S.G. Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzyme. Structure 2002, 10:1569-1580.
54. Oksman M., Iivonen H., Hogyes E., Amtul Z., Penke B., Leenders I., Broersen L., Lutjohann D., Hartmann T., Tanila H. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 2006, 23:563-572.
55. Patil S., Melrose J., Chan C. Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur. J. Neurosci. 2007, 26:2131-2141.
56. Pedrini S., Thomas C., Brautigam H., Schmeidler J., Ho L., Fraser P., Westaway D., Hyslop P.S., Martins R.N., Buxbaum J.D., Pasinetti G.M., Dickstein D.L., Hof P.R., Ehrlich M.E., Gandy S. Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathology. Mol. Neurodegener. 2009, 4:1326-1366.
57. Perry D.K., Carton J., Shah A.K., Meredith F., Uhlinger D.J., Hannun Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 2000, 275:9078-9084.
58. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J Biol Chem. 2003, 278:19777-19783.
59. Quartermain D., Mower J., Rafferty M.F., Herting R.L., Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur. J. Pharmacol. 1994, 257:7-12.
60. Resende R., Ferreiro E., Pereira C., Oliveira C.R. ER stress is involved in Abeta-induced GSK-3beta activation and tau phosphorylation. J. Neurosci. Res. 2008, 86:2091-2099.
61. Samad F., Hester K.D., Yang G., Hannun Y.A., Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006, 55:2579-2587.
62. Satoi H., Tomimoto H., Ohtani R., Kitano T., Kondo T., Watanabe M., Oka N., Akiguchi I., Furuya S., Hirabayashi Y., Okazaki T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130:657-666.
63. Sawamura N., Ko M., Yu W., Zou K., Hanada K., Suzuki T., Gong J.S., Yanagisawa K., Michikawa M. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J. Biol. Chem. 2004, 279:11984-11991.
64. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nature Med. 2008, 14:1106-1111.
65. Schmelz E.M., Dombrink-Kurtzman M.A., Roberts P.C., Kozutsumi Y., Kawasaki T., Merrill A.H. Induction of apoptosis by fumonisin B1 in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol. Appl. Pharmacol. 1998, 148:252-260.
66. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2008, 105:14052-14057.
67. Schuster G.M., Schmidt W.J. D-cycloserine reverses the working memory impairment of hippocampal-lesioned rats in a spatial learning task. Eur. J. Pharmacol. 1992, 224:97-98.
68. Shah C., Yang G., Lee I., Bielawski J., Hannun Y.A., Samad F. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J. Biol. Chem. 2008, 283:13538-13548.
69. Sheehan D.C. Theory and practice of histotechnology 1980, Battelle press, St. Louis: Mosby. second ed.
70. Sisodia S.S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U. S. A 1992, 89:6075-6079.
71. Strettoi E., Gargini C., Novelli E., Sala G., Piano I., Gasco P., Ghidoni R. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A 2010, 107:18706-18711.
72. Stromme Johannesen T., Myhrer T. Impaired visual memory in rats reared in isolation is reversed by D-cycloserine in the adult rat. Eur J Pharmacol. 2002, 437:73-77.
73. Sundaram K.S., Lev M. L-cycloserine inhibition of sphingolipid synthesis in the anaerobic bacterium Bacteroides levii. Biochem. Biophys. Res. Commun. 1984, 119:814-819.
74. Sundaram K.S., Lev M. Inhibition of sphingolipid synthesis by cycloserine in vitro and in vivo. J. Neurochem. 1984, 42:577-581.
75. Sundaram K.S., Lev M. Inhibition of cerebroside synthesis in the brains of mice treated with L-cycloserine. J. Lipid Res. 1985, 26:473-477.
76. Sundaram K.S., Lev M. The long-term administration of L-cycloserine to mice: specific reduction of cerebroside level. Neurochem. Res. 1989, 14:245-248.
77. Tomiyama T., Matsuyama S., Iso H., Umeda T., Takuma H., Ohnishi K., Ishibashi K., Teraoka R., Sakama N., Yamashita T., Nishitsuji K., Ito K., Shimada H., Lambert M.P., Klein W.L., Mori H. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 2010, 30:4845-4856.
78. Tsai G.E., Falk W.E., Gunther J., Coyle J.T. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am. J. Psychiatry 1999, 156:467-469.
79. Turinsky J., Bayly B.P., O'Sullivan D.M. 1,2-Diacylglycerol and ceramide levels in rat skeletal muscle and liver in vivo. Studies with insulin, exercise, muscle denervation, and vasopressin. J. Biol. Chem. 1990, 265:7933-7938.
80. Unger R.H., Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 2001, 15:312-321.
81. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-660.
82. Vetrivel K.S., Cheng H., Kim S.H., Chen Y., Barnes N.Y., Parent A.T., Sisodia S.S., Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 2005, 280:25892-25900.
83. Vetrivel K.S., Cheng H., Lin W., Sakurai T., Li T., Nukina N., Wong P.C., Xu H., Thinakaran G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J. Biol. Chem. 2004, 279:44945-44954.
84. Wada S., Morishima-Kawashima M., Qi Y., Misono H., Shimada Y., Ohno-Iwashita Y., Ihara Y. Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 2003, 42:13977-13986.
85. Wagner J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 2008, 48:631-651.
86. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., Golde T.E. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 2002, 9:11-23.
87. Wang G., Dinkins M., He Q., Zhu G., Poirier C., Campbell A., Mayer-Proschel M., Bieberich E. Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). J. Biol. Chem. 2012, 287:21384-21395.
88. Williams R.D., Sgoutas D.S., Zaatari G.S., Santoianni R.A. Inhibition of serine palmitoyltransferase activity in rabbit aorta by L-cycloserine. J. Lipid. Res. 1987, 28:1478-1481.
89. Won J.S., Im Y.B., Khan M., Contreras M., Singh A.K., Singh I. Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J. Neurochem. 2008, 105:1536-1549.
90. Wu D., Hu T., Zhang L., Chen J., Du J., Ding J., Jiang H., Shen X. Residues Asp164 and Glu165 at the substrate entryway function potently in substrate orientation of alanine racemase from E. coli: enzymatic characterization with crystal structure analysis. Protein Sci. 2008, 17:1066-1076.
91. Yasuda S., Nishijima M., Hanada K. Localization, topology, and function of the LCB1 subunit of serine palmitoyltransferase in mammalian cells. J. Biol. Chem. 2003, 278:4176-4183.
92. Yoshizawa T., Yamashita A., Luo Y. Fumonisin occurrence in corn from high- and low-risk areas for human esophageal cancer in China. Appl. Environ. Microbiol. 1994, 60:1626-1629.
93. Zendzian-Piotrowska M., Baranowski M., Zabielski P., Gorski J. Effects of pioglitazone and high-fat diet on ceramide metabolism in rat skeletal muscles. J. Physiol. Pharmacol. 2006, 57(Suppl 10):101-114.
94. Zha Q., Ruan Y., Hartmann T., Beyreuther K., Zhang D. GM1 ganglioside regulates the proteolysis of amyloid precursor protein. Mol. Psychiatry 2004, 9:946-952.